A phase 1a, single-dose, open-label, parallel, ascending dose, controlled safety and tolerability trial of inhaled MKC253 in healthy adult male subjects.
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2012
At a glance
- Drugs Glucagon-like peptide-1 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 13 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 08 Nov 2007 Status change from in progress to completed.